Therewith the therapeutic plan aims to control tumor growth, normalize, or reduce hormonal hypersecretion of GH and IGF-1, but also a long-term goal is to reduce the rates of morbidity and mortality, which are much higher in patients with acromegaly compared to the general population [4,5]. The gene discussed is GH1; the disease is neoplasm.